ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

ClinicalTrials.gov ID: NCT06651281

Public ClinicalTrials.gov record NCT06651281. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 5:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Extension Study to Evaluate the Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis

Study identification

NCT ID
NCT06651281
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
1,380 participants

Conditions and interventions

Interventions

  • Placebo to tulisokibart Drug
  • Tulisokibart Drug

Drug

Eligibility (public fields only)

Age range
Not listed
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 24, 2024
Primary completion
Dec 16, 2037
Completion
Dec 16, 2037
Last update posted
Dec 25, 2025

2024 – 2037

United States locations

U.S. sites
12
U.S. states
7
U.S. cities
11
Facility City State ZIP Site status
Connecticut Clinical Research Institute ( Site 0297) Bristol Connecticut 06010 Recruiting
St. Joseph Mercy Hospital - Huron Gastroenterology Associates ( Site 0287) Ypsilanti Michigan 48197 Recruiting
BVL Research - Kansas ( Site 0292) Liberty Missouri 64068 Recruiting
New York Gastroenterology Associates ( Site 0253) New York New York 10075 Recruiting
GI Alliance - Digestive Health Associates of Texas - DHAT ( Site 0290) Garland Texas 75044 Recruiting
GI Alliance - Lubbock ( Site 0288) Lubbock Texas 79410 Recruiting
Caprock Gastro Research ( Site 0293) Lubbock Texas 79424 Recruiting
Southern Star Research Institute ( Site 0299) San Antonio Texas 78229 Recruiting
GI Alliance - Southlake ( Site 0298) Southlake Texas 76092-9167 Recruiting
Tyler Research Institute ( Site 0294) Tyler Texas 75701 Recruiting
University of Virginia Health System ( Site 0291) Charlottesville Virginia 22908 Recruiting
Washington Gastroenterology - Tacoma ( Site 0295) Tacoma Washington 98405 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06651281, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 25, 2025 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06651281 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →